Ablynx, GlaxoSmithKline antibodies news

GlaxoSmithKline's Domantis Ltd. subsidiary filed a request for arbitration against Ablynx related to the interpretation of a June 2005 settlement under which Domantis granted Ablynx rights to use individual heavy chain antibody domains that were generated with expression libraries. Domantis alleges that Ablynx is performing activities that are not permitted under the terms of the settlement. ...